Background and Purpose The multikinase inhibitor sorafenib is a first‐line drug for
advanced hepatocellular carcinoma. The response to sorafenib varies among …

Sorafenib resistance is a major challenge in the therapy for advanced hepatocellular
carcinoma (HCC). However, the underlying molecular mechanisms of HCC resistance to …

Hepatocellular carcinoma (HCC) incidence, as well as related mortality, has been steadily
increasing in the USA and across the globe, partly due to the lack of effective therapeutic …

Sorafenib is the first FDA-approved therapeutic drug for molecular target medication on
advanced-stage hepatocellular carcinoma. It is reported that sorafenib could improve the …

Sorafenib is a first-line drug to treat advanced hepatocellular carcinoma (HCC), which can
prolong the median overall survival of patients by approximately 3 months. Phenformin is a …

Objective: In light of the upregulation of p21-activated kinase (PAK7) in a variety of cancers,
including hepatocellular carcinoma (HCC), we aimed to investigate the effect of PAK7 on the …

Sorafenib is the first‑line drug used in the treatment of liver cancer; however, drug resistance
seriously limits the clinical response to sorafenib. The present study investigated the …

Objective: To detect the expression level of YES-associated protein 1 (YAP) in
hepatocellular carcinoma (HCC) cell lines and investigate its effects on the proliferation …

Hepatocellular carcinoma (HCC) is the most common liver malignancy, and the lack of
effective chemotherapies underlines the need for novel therapeutic approaches for this …

Hepatocellular carcinoma (HCC) is the most common primary cancer worldwide. The only
current drug available for clinical treatment of HCC is sorafenib, which inhibits multiple …